Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder

Urinary Bladder, Overactive Clinical Trial

Official title:

Comparison of the Efficacy of Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05668715
• Other study ID #: pamukkaleu.ftr.NYildiz.001
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: June 30, 2023

Study information

• Verified date: December 2022
• Source: Pamukkale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study is the first prospective trial that compares the efficacy of TTNS in antimuscarinic naive and refractory women with idiopathic OAB. In this study, it was aimed to compare the effectiveness of TTNS on quality of life (QoL) and clinical parameters related to OAB in antimuscarinic naive and refractory women. The results of this study would make it easier to understand the place of TTNS among the treatment options in women with idiopathic OAB.

Description:

This study was planned as a prospective clinical trial. The trial was carried out in the Urogynecological Rehabilitation Unit of Physical Medicine and Rehabilitation Department, in between January 2023 and June 2023. The local ethics committee approved the study. All women were informed about the purpose and contents of the study and all women signed written consent to participate in the study. As previously published by Sonmez et al , BT+IVES succeeded to reduce mean incontinence episodes from 4.40±3.43 to 0.70±0.57 after treatment in the active comparator group while mean incontinence episodes was reduced from 4.15±1.67 to 2.68±1.66 after treatment in the control group (BT). Considering a 50% or greater improvement in incontinence episodes in the referred study, the optimum sample size should be 18 cases in each arm with a level of significance of 95% (α=5%), a power of 95% (ß=0.05) . Taking into account possible withdrawals which was assumed to be about 10% of the number of patients, a total of 40 women (20 women for each group) were calculated for this study. Sample size calculation was performed by the physician using G*Power 3.1 Statistical Power Analysis for Microsoft Windows and Mac. Statistics. To investigators recruited women with complaints of OAB who were referred to the Urogynecological Rehabilitation Unit and other related outpatient clinics. Women over the age of 18 with the clinical diagnosis of idiopathic OAB, and who could able to give written informed consent and understand the procedures were included in this study. The criteria for exclusion were as follows. Women who had stress urinary incontinence; a history of PTNS and/or TTNS for OAB within 6 months; urogynecological surgery within 3 months; current vulvovaginitis or urinary tract infections or malignancy; pregnancy; cardiac pacemaker or implanted defibrillator; anatomic or posttraumatic malformations/skin disorders of tibial nerve region on inner ankle that can not allow to apply the electrodes; the strength of PFM less than 3/5 (graded as modified Oxford scale, min:0-max:5); the pelvic organ prolapse quantification (POP-Q) (stage 2 or more); neurogenic bladder; the peripheral or central neurologic pathology; ultrasonographic evidence of post-void residual urine volume more than 100 ml were excluded. Women with idiopathic OAB were recruited for eligibility and of them who fulfilled the inclusion/exclusion criteria were included for this study. Antimuscarinic naive women were included in Group 1 (n:20), and women resistant to anti-muscarinic agents were included in Group 2 (n:20). Both groups received BT plus TTNS. Group 1: Antimuscarinic Naive (AM-N) None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group. Group 1: Antimuscarinic Refractory (AM-R) Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group. Bladder Training (BT) All women were informed about BT that consisted of four stages and lasted for 30 minutes. Then, it was given as a written brochure to be implemented as a home program. At the first stage, the women were familiarized with the location of the PFM and the pelvic anatomy and pathophysiology. After that information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage including urgency suppression strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply, giving their attention to another job for a while, and self-motivating. In the third stage, a timed voiding program was started. It was carried out in 2 steps: a timed voiding and increasing the time between urination considering the voiding diary. At the last stage, the women were encouraged to continue BT. Transcutaneous tibial nerve stimulation (TTNS) Two self-adhesive surface electrodes were positioned according to the protocol used by Booth et al and Shreiner et al, with the negative electrode 2 cm behind the medial malleolus and positive electrode 10 cm proximal to it. Correct positioning was determined by noting a hallux reaction (plantar flexion of great toe or fanning of all toes). The stimulation protocol was delivered at fixed of 20 Hz and pulse width of 200 ms in continous mode in accordance with PTNS stimulation protocol. The intensity level of the stimulation current (range 0-50 mA) was determined once correct positioning was established, according to the comfort level of the subject. TTNS sessions were performed two times in a week, for 6 weeks. Every session lasted 30 minutes. The intervention comprised a 12 session treatment program of TTNS. TTNS sessions were performed by an experienced urogynecological rehabilitation nurse in all groups. During the treatment, all women were advised to continue the medical treatment which was not related to incontinence. Participants were asked to fill in a one-day bladder diary biweekly to continue the timed voiding program, which is part of BT in two groups. Compliance with the BT was achieved with the daily checklist during 6 weeks and the bladder diaries of women were checked biweekly to rearrange the timed voiding program. Women who did not fill more than 20% of the daily checklist and who missed any therapy sessions for two groups were excluded from the study. Evaluation Parameters The primary outcome measure was accepted as the improvement in incontinence episodes (positive response rate), according to literature . To determine positive response rate, reduction in incontinence episodes was collected from the 3-day bladder diary. Women with ≥a 50% reduction in incontinence episodes were considered positive responders. Furthermore, the severity of incontinence, PFM strength, symptom severity, frequency of voiding, nocturia, number of pads as well as QoL were secondary outcome measures. The 24-hour pad test was carried out to evaluate the severity of incontinence. Overactive Bladder Questionnaire (OAB-V8) was used to evaluate the symptom severity in patients with OAB in this study. The OAB-V8 consists of 8 questions in which the patients can be classified with respect to the symptom severity: none (0), very little (1), a little (2), quite a few (3), very (4), and too many (5). The total score ranges from 0-40. The frequencies of voiding, nocturia, and the number of pads used were collected from the 3-day bladder diary. The Quality of Life-Incontinence Impact Questionnaire (IIQ7) was used to assess specific QoL related to incontinence. In addition, cure-improvement rate and treatment satisfaction were evaluated. In a 24-hour pad test, amount of urine that was under 1.3 gr was considered as a cure. The improvement rate was assessed in terms of 50% and more reduction in wet weight compared to baseline measurements in the 24-hour pad test . Women evaluated the change in their urinary incontinence on a 5-point Likert scale (5, very satisfied; 1, very unsatisfied). All the evaluation tests were performed by another physician who was blinded to the groups in the initial visit and at the end of the treatment (8th week), except for the positive response rate, cure/improvement rate, and the treatment satisfaction parameters which were evaluated only at the 8th week. Statistics SPSS17.0 software (SPSS, Chicago, IL) was used for the statistical analysis. In each group, measurable parameters were tested with the Kolmogorov-Smirnov test for the evaluation of normal distribution. Because the distributions were not normal, non-parametric tests were used in the statistical evaluation. Mann-Whitney U-test and χ2 test were used for inter-group comparisons. Wilcoxon tests were used for intra-group comparison of parameters at different point of times. P<0.05 was accepted as statistically significant.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: June 30, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Women 18 years and older with clinically idiopathic OAB

2. Having the ability to give written informed consent

3. Ability to understand procedures

Exclusion Criteria:

1. Presence of active vaginal or urinary tract infection or malignancy

2. Pregnancy or intention to become pregnant during the study

3. History of neurogenic bladder, peripheral or central neurological pathology

4. Presence of Grade 2 and higher pelvic organ prolapse (POP) according to the International Continence Society (ICS)

5. Having undergone urogynecological surgery in the last 3 months

6. Women with stress urinary incontinence

7. History of PTNS and/or TTNS for OAB in the past 6 months

8. Presence of a pacemaker or implanted defibrillator

9. Presence of anatomical or post-traumatic malformations / skin disorders of the tibial nerve region of the inner ankle that do not allow the application of electrodes

10. PTK strength less than 3/5 (rated as modified Oxford scale, min: 0-max: 5)

11. Ultrasonographic evidence of a postvoid residual urine volume greater than 100 ml

Related Conditions & MeSH terms

• Urinary Bladder, Overactive

Intervention

Other:
• Transcutaneous tibial nerve stimulation (TTNS)
PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years

Locations

Country	Name	City	State
Turkey	Pamukkale University	Denizli

Sponsors (1)

Lead Sponsor	Collaborator
Pamukkale University

Country where clinical trial is conducted

Turkey, 

References & Publications (28)

Abdelbary AM, El-Dessoukey AA, Massoud AM, Moussa AS, Zayed AS, Elsheikh MG, Ghoneima W, Abdella R, Yousef M. Combined Vaginal Pelvic Floor Electrical Stimulation (PFS) and Local Vaginal Estrogen for Treatment of Overactive Bladder (OAB) in Perimenopausal Females. Randomized Controlled Trial (RCT). Urology. 2015 Sep;86(3):482-6. doi: 10.1016/j.urology.2015.06.007. Epub 2015 Jun 30. — View Citation

Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS, Oh SJ. Translating overactive bladder questionnaires in 14 languages. Urology. 2006 Mar;67(3):536-40. doi: 10.1016/j.urology.2005.09.035. Erratum In: Urology. 2007 Jan;69(1):202. Oh, Seung June [added]. — View Citation

Amaro JL, Gameiro MO, Kawano PR, Padovani CR. Intravaginal electrical stimulation: a randomized, double-blind study on the treatment of mixed urinary incontinence. Acta Obstet Gynecol Scand. 2006;85(5):619-22. doi: 10.1080/00016340500495058. — View Citation

Barroso JC, Ramos JG, Martins-Costa S, Sanches PR, Muller AF. Transvaginal electrical stimulation in the treatment of urinary incontinence. BJU Int. 2004 Feb;93(3):319-23. doi: 10.1111/j.1464-410x.2004.04608.x. — View Citation

Berghmans B, van Waalwijk van Doorn E, Nieman F, de Bie R, van den Brandt P, Van Kerrebroeck P. Efficacy of physical therapeutic modalities in women with proven bladder overactivity. Eur Urol. 2002 Jun;41(6):581-7. doi: 10.1016/s0302-2838(02)00178-1. — View Citation

Berghmans LC, Hendriks HJ, De Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int. 2000 Feb;85(3):254-63. doi: 10.1046/j.1464-410x.2000.00434.x. — View Citation

Bo K, Frawley HC, Haylen BT, Abramov Y, Almeida FG, Berghmans B, Bortolini M, Dumoulin C, Gomes M, McClurg D, Meijlink J, Shelly E, Trabuco E, Walker C, Wells A. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Int Urogynecol J. 2017 Feb;28(2):191-213. doi: 10.1007/s00192-016-3123-4. Epub 2016 Dec 5. — View Citation

Booth J, Hagen S, McClurg D, Norton C, MacInnes C, Collins B, Donaldson C, Tolson D. A feasibility study of transcutaneous posterior tibial nerve stimulation for bladder and bowel dysfunction in elderly adults in residential care. J Am Med Dir Assoc. 2013 Apr;14(4):270-4. doi: 10.1016/j.jamda.2012.10.021. Epub 2012 Nov 30. — View Citation

Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al. The European Association of Urology (EAU) Guidelines. EAU Guidelines on urinary incontinence in adults. In: EAU Guidelines, 2018 (Internet). Available online at: http://uroweb.org/guideline/urinary-incontinence/

Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourol Urodyn. 2007;26(1):129-33. doi: 10.1002/nau.20292. — View Citation

Firinci S, Yildiz N, Alkan H, Aybek Z. Which combination is most effective in women with idiopathic overactive bladder, including bladder training, biofeedback, and electrical stimulation? A prospective randomized controlled trial. Neurourol Urodyn. 2020 Nov;39(8):2498-2508. doi: 10.1002/nau.24522. Epub 2020 Sep 22. — View Citation

Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015 May;193(5):1572-80. doi: 10.1016/j.juro.2015.01.087. Epub 2015 Jan 23. — View Citation

Kasman A, Stave C, Elliott CS. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature. Neurourol Urodyn. 2019 Nov;38(8):2083-2092. doi: 10.1002/nau.24158. Epub 2019 Sep 4. — View Citation

La Rosa VL, Platania A, Ciebiera M, Garzon S, Jedra R, Ponta M, Buttice S. A comparison of sacral neuromodulation vs. transvaginal electrical stimulation for the treatment of refractory overactive bladder: the impact on quality of life, body image, sexual function, and emotional well-being. Prz Menopauzalny. 2019 Jun;18(2):89-93. doi: 10.5114/pm.2019.86834. Epub 2019 Jun 28. — View Citation

Lee HE, Cho SY, Lee S, Kim M, Oh SJ. Short-term Effects of a Systematized Bladder Training Program for Idiopathic Overactive Bladder: A Prospective Study. Int Neurourol J. 2013 Mar;17(1):11-7. doi: 10.5213/inj.2013.17.1.11. Epub 2013 Mar 31. — View Citation

Manriquez V, Guzman R, Naser M, Aguilera A, Narvaez S, Castro A, Swift S, Digesu GA. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016 Jan;196:6-10. doi: 10.1016/j.ejogrb.2015.09.020. Epub 2015 Oct 20. — View Citation

O'Sullivan R, Karantanis E, Stevermuer TL, Allen W, Moore KH. Definition of mild, moderate and severe incontinence on the 24-hour pad test. BJOG. 2004 Aug;111(8):859-62. doi: 10.1111/j.1471-0528.2004.00211.x. — View Citation

Ramirez-Garcia I, Blanco-Ratto L, Kauffmann S, Carralero-Martinez A, Sanchez E. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial. Neurourol Urodyn. 2019 Jan;38(1):261-268. doi: 10.1002/nau.23843. Epub 2018 Oct 12. — View Citation

Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2017 Jan-Feb;43(1):121-126. doi: 10.1590/S1677-5538.IBJU.2015.0719. — View Citation

Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J. 2010 Sep;21(9):1065-70. doi: 10.1007/s00192-010-1165-6. Epub 2010 May 11. — View Citation

Sonmez R, Yildiz N, Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. Ann Phys Rehabil Med. 2022 Jan;65(1):101486. doi: 10.1016/j.rehab.2021.101486. Epub 2021 Nov 11. — View Citation

Tarcan T, Mangir N, Özgür MÖ, Akbal C. OAB-V8 Overactive Bladder Questionnaire Validation Study. (Turkish) Üroloji Bülteni 2012;21:113-116. http://www.kontinansdernegi.org/userfiles/media/kontinans.galenos.com.tr/oab-v8-asiri-aktif-mesane-sorgulama-formu.pdf

Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology. 2006 Nov;68(5):999-1004. doi: 10.1016/j.urology.2006.05.038. — View Citation

Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004 Jan;63(1):61-6. doi: 10.1016/j.urology.2003.08.047. — View Citation

Wang S, Lv J, Feng X, Lv T. Efficacy of Electrical Pudendal Nerve Stimulation versus Transvaginal Electrical Stimulation in Treating Female Idiopathic Urgency Urinary Incontinence. J Urol. 2017 Jun;197(6):1496-1501. doi: 10.1016/j.juro.2017.01.065. Epub 2017 Jan 31. — View Citation

Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Suda S. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. Urology. 2000 Mar;55(3):353-7. doi: 10.1016/s0090-4295(99)00476-8. — View Citation

Yildiz N, Alkan H, Findikoglu G. Efficacy of intravaginal electrical stimulation with different treatment frequency in women with refractory idiopathic overactive bladder. Int Braz J Urol. 2022 Jul-Aug;48(4):662-671. doi: 10.1590/S1677-5538.IBJU.2021.0837. — View Citation

Yildiz N, Alkan H, Sarsan A. Efficacy of intravaginal electrical stimulation added to bladder training in women with idiopathic overactive bladder: A prospective randomized controlled trial. Int Braz J Urol. 2021 Nov-Dec;47(6):1150-1159. doi: 10.1590/S1677-5538.IBJU.2021.0161. — View Citation

* Note: There are 28 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in incontinence episodes	To determine positive response rate, reduction in incontinence episodes was collected from the 3-day bladder diary. Women with =a 50% reduction in incontinence episodes were considered positive responders	6 months
Secondary	Severity of incontinence	The 24-hour pad test and Overactive Bladder Questionnaire (OAB-V8) was carried out to evaluate the severity of incontinence. The OAB-V8 consists of 8 questions in which the patients can be classified with respect to severity of incontinence: none (0), very little (1), a little (2), quite a few (3), very (4), and too many (5). The total score ranges from 0-40.	6 months
Secondary	The frequencies of voiding	TThe frequencies of voiding, used were collected from the 3-day bladder diary.	6 months
Secondary	Cure-improvement rate	In a 24-hour pad test, amount of urine that was under 1.3 gr was considered as a cure. The improvement rate was assessed in terms of 50% and more reduction in wet weight compared to baseline measurements in the 24-hour pad test.	6 months
Secondary	Change in their urinary incontinence	Women evaluated the change in their urinary incontinence on a 5-point Likert scale (5, very satisfied; 1, very unsatisfied)	6 months
Secondary	Nocturia	Nocturia, used were collected from the 3-day bladder diary.	6 months
Secondary	The number of pads	The number of pads, used were collected from the 3-day bladder diary.	6 months
Secondary	The Quality of Life	The Quality of Life-Incontinence Impact Questionnaire (IIQ7) was used to assess specific QoL related to incontinence. The form consists of 7 questions. In the form, the patients had no complaints (0); less (1); middle (2); many (3); graded as. The total score ranges from 0 to 21. A lower score indicates less quality of life impact.	6 months
Secondary	Treatment satisfaction	A 5-point "treatment satisfaction scale" was used for treatment satisfaction. (1, not at all satisfied 5, very satisfied). A lower score indicates less treatment satisfaction.	6 months